IRD Opus Genetics, Inc.
Company Analysis
Latest News
🟢 Opus Genetics is trading 6.7% up today ahead of September 9 Cohort 1 data webcast
Opus Genetics is trading at $4.75 (+6.72%) after its September 2 announcement of a September 9 webcast presenting topline Cohort 1 data from the Phase 1/2...
🟢 Opus Genetics is trading 6.1% up in pre-market ahead of September 9 topline data webcast
Opus Genetics is trading 6.1% up in pre-market at $4.72 after announcing a September 9 investor webcast for topline Cohort 1 data from its Phase 1/2 OPGx-BEST1...
Opus Genetics Surges on Bet That Gene Therapy Data Will Deliver — But Can a $4 Stock Survive a Binary Catalyst?
Shares of Opus Genetics (IRD) jumped 10.2% to $4.22 on September 2, extending a two-day rally of roughly 16.6% as traders pile into the micro-cap ahead of...
🟢 Opus Genetics is trading 10% up today ahead of expected OPGx-BEST1 Cohort 1 topline data
Opus Genetics is trading 10% up now at $4.22 on speculative positioning ahead of expected three-month topline data from the OPGx-BEST1 Cohort 1 study during...
🟢 Opus Genetics is trading 5% up today ahead of expected September 2026 topline data
Opus Genetics is trading 5% up now at $4.03, with the move appearing driven by speculative positioning ahead of three-month topline data from the OPGx-BEST1...
🟢 Opus Genetics is trading 5% up today amid speculative positioning ahead of unconfirmed September data
Opus Genetics is trading 5.11% up now at $3.81, with the move appearing consistent with speculative positioning ahead of anticipated three-month OPGx-BEST1...
🟢 Opus Genetics is trading 7.46% up in pre-market possibly reflecting positioning ahead of clinical data
Opus Genetics is trading 7.46% up at $3.89, with gains possibly reflecting speculative positioning ahead of clinical data, though no fresh company-specific...
🔴 Opus Genetics is trading 5% down today amid broader biotech weakness
Opus Genetics is trading 5.19% down now at $3.65, with the decline appearing primarily linked to broader biotech weakness; no company-specific catalyst was...
🟢 Opus Genetics is trading 5.19% up in pre-market with no direct catalyst identified
Opus Genetics is trading at $4.05, up 5.19% after rising from the $3.85 August 27 close; no direct catalyst has been confirmed. - No new company-specific...
🟢 Opus Genetics is trading 11.58% up in pre-market after Nvidia beat expectations
Opus Genetics is trading at $4.24, up +11.58%, as broader risk appetite improved after Nvidia beat expectations. - No new Opus Genetics company-specific...
🔴 Opus Genetics is trading 5% down today
Opus Genetics is trading 5.11% down now at $3.90, with no new company-specific announcement identified on August 26, 2026, leaving the catalyst unclear. -...
🟢 Opus Genetics is trading 9.25% up in pre-market
Opus Genetics is trading 9.25% up now at $4.49, with no new company-specific announcement identified for August 26, 2026. - Latest major updates were August 6...
🟢 Opus Genetics is trading 8.2% up today amid biotech ETF XBI’s 2.06% gain
Opus Genetics is trading 8.2% up at $4.36, with biotech-sector momentum the strongest explanation. - No newly identified company-specific announcement was...
🟢 Opus Genetics is trading 5.93% up in pre-market
Opus Genetics is trading at $4.29 (+5.93%) in pre-market, with no clear company-specific catalyst identified. - No clear company-specific announcement was...
🟢 Opus Genetics rises 5.1% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 Opus Genetics is trading 7.18% up in pre-market after renewed Phase 3 focus
Opus Genetics is trading at $3.96, up 7.18%, after renewed investor focus on completing enrollment in the registrational Phase 3 OPGx-LCA5 trial. - The...
🟢 Opus Genetics is trading 6.58% up in pre-market after Phase 3 enrollment completion
Opus Genetics is trading 6.58% up in pre-market at $3.89 after renewed investor focus on its completed Phase 3 enrollment milestone for OPGx-LCA5. • The...
Opus Genetics Hits a Key Trial Milestone, But Can an Ultra-Rare Gene Therapy Justify Its $280 Million Bet?
Shares of Opus Genetics (IRD) surged 10.5% to $3.99 on August 17, buoyed by renewed investor focus on the company's completed enrollment in its pivotal...
🟢 Opus Genetics is trading 11% up in pre-market after completed Phase 3 OPGx-LCA5 enrollment
Opus Genetics is trading at $3.99 (+10.53%) in pre-market on August 17, 2026, after renewed attention to its completed enrollment in the registrational Phase 3...
🟢 Opus Genetics is trading 7.45% up in pre-market — no clear catalyst identified
Opus Genetics is trading 7.45% up at $4.04, with no clear company-specific catalyst identified for August 13, 2026. - The latest confirmed corporate update...